Company: RNAC
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001453687-25-000075
Chunk: 67

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 67
---
 Officer, with such a “gross-up” or other reimbursement payment.

Accounting for Stock-Based Compensation

The Compensation Committee takes accounting considerations into account in designing compensation plans and arrangements for our executive officers and other employees. Chief among these is Financial Accounting Standards Board Accounting Standards Codification Topic 718 (“ASC Topic 718”), the standard which governs the accounting treatment of stock-based compensation awards.

ASC Topic 718 requires us to recognize in our financial statements all share-based payment awards to employees, including grants of options to purchase shares of our Common Stock and restricted stock awards for shares of our Common Stock to our executive officers, based on their fair values. The application of ASC Topic 718 involves significant amounts of judgment in the determination of inputs into the Black-Scholes-Merton valuation model that we use to determine the fair value of stock options. These inputs are based upon assumptions as to the volatility of the underlying stock, risk free interest rates, and the expected life (term) of the options. As required under GAAP, we review our valuation assumptions at each grant date, and, as a result, our valuation assumptions used to value stock options granted in future periods may vary from the valuation assumptions we have used previously. For performance-based stock awards, we also must apply judgment in determining the periods when, and if, the related performance targets become probable of being met.

ASC Topic 718 also requires us to recognize the compensation cost of our share-based payment awards in our income statement over the period that an employee, including one of our executive officers, is required to render service in exchange for the award (which, generally, will correspond to the award’s vesting schedule).

<div align='center'>39</div>

#### Executive and Director Compensation

#### Executive Compensation
This section discusses the material components of the executive compensation program offered to our Named Executive Officers identified below. For 2024, our Named Executive Officers and their positions as of December 31, 2024 were:

• Carsten Brunn, Ph.D., our President and CEO;

• Blaine Davis, our CFO;

• Christopher Jewell, Ph.D., our Chief Scientific Officer; and

• Metin Kurtoglu, M.D., Ph.D., who served as our Chief Operating Officer from November 13, 2023 until March 28, 2024, and then continued to serve as our Chief Technology Officer.

#### 2024 Summary Compensation Table
| Name and principal position    |     | Year |     | Salary 
 ($)(1) |